Solid Biosciences Inc. — Director's Dealing 2022

Dec 5, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Solid Biosciences Inc. (SLDB)
CIK: 0001707502
Period of Report: 2022-12-02

Reporting Person: Cumbo Alexander (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-12-02	Common Stock	A	584	—	Acquired	584	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-12-02	Stock Option (Right to Buy)	$6.77	A	228900	Acquired	2032-12-02	Common Stock (228900)	Direct
2022-12-02	Restricted Stock Units	$	A	114449	Acquired		Common Stock (114449)	Direct

Footnotes

F1: The reporting person acquired 584 shares of the issuer's common stock pursuant to the issuer's acquisition of all of the outstanding capital stock of AavantiBio, Inc. on December 2, 2022.

F2: This option was granted on December 2, 2022 (the "Grant Date") and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the Grant Date and 2.0833% of the original number of shares on the first day of each calendar month thereafter until the fourth such anniversary.

F3: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs").

F4: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.